India, May 17 -- Alnylam Pharmaceuticals Inc. (ALNY) announced that results from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) demonstrate that the drug effectively reduces key cardiovascular (CV) events, including CV hospitalizations and heart failure (HF) hospitalizations.
Additionally, in the analysis, urgent HF visits were reduced by 46% in the overall population during the double-blind period, compared to placebo. The cardiovascular events often precede all-cause mortality (ACM) and are key indicators of disease progression.
Importantly, results from the November 2024 data cut, including further follow up through up to 42 months, reinforce the primary HELIOS-B ...